The drug that made Novo Nordisk briefly the most valuable company in Europe, created global shortages, and put the word “semaglutide” into everyday conversation has just gone off patent in India. As of March 21, 2026, the molecule behind Ozempic and Wegovy is open for competition — and Indian pharma is treating it like the starting gun of the most consequential race in the industry’s history.
On March 17, Zydus Lifesciences and Lupin announced a licensing and co-marketing agreement that brings the total number of brands entering the Indian semaglutide market to five from these two companies alone — Semaglyn, Mashema and Alterme from Zydus, and Semanext and Livarise from Lupin. It is the latest move in what industry insiders are calling a gold rush, and it illustrates exactly how the battle for India’s semaglutide market will be won — not just on price, but on distribution, device innovation and physician relationships.
Zydus and Lupin sign agreement to co-market Semaglutide injection in India
What Semaglutide Is and Why It Matters
Semaglutide is a GLP-1 receptor agonist — a class of drug that mimics a hormone called glucagon-like peptide-1, which regulates blood sugar and appetite. It was originally developed by Novo Nordisk for type 2 diabetes under the brand name Ozempic. At higher doses, it became Wegovy for chronic weight management. The results in both indications were dramatic enough to create waiting lists at pharmacies across the United States and Europe.
India’s weight management market was valued at $27.4 billion in 2025 and is projected to grow to $56.79 billion by 2034. Goldman Sachs has estimated the global anti-obesity drug market could grow to over $100 billion in the next decade. The India GLP-1 receptor agonist market was estimated at USD 110.55 million in 2024 and is projected to grow at a CAGR of 34.3% from 2025 to 2030.
India has one of the world’s largest diabetes burdens — approximately 8.9 crore adults with the condition — and obesity rates in urban areas are rising sharply. The market was waiting for an affordable version of semaglutide. As of March 21, it has one. It will soon have dozens.
The Patent Expiry: What Just Opened Up
Semaglutide’s patent expired on March 20, clearing the path for more than half a dozen companies including Sun Pharma, Zydus Lifesciences, Dr Reddy’s and Natco Pharma to enter the market from Day 1, March 21.
In India, patents covering semaglutide’s composition and delivery expired or will expire by March 2026, allowing local drugmakers to enter the highly lucrative anti-obesity and diabetes space with their own versions. More than two dozen Indian pharmaceutical firms are preparing to launch semaglutide-based generics under a bewildering array of names.
Until now, semaglutide therapies were sold at high prices, limiting access for many patients. A monthly starter dose costs close to ₹10,000. Industry analysts expect that once generics enter from March 21, prices could drop to ₹3,500 to ₹4,000 for starter doses.
The Prize: How Big Is This Really?
The expiration of semaglutide’s patent across India, emerging economies and select regulated markets like Canada and Brazil could unlock a revenue pool exceeding ₹50,000 crore for generic drugmakers over the next 12 to 15 months.
The Indian market is expected to see a ₹1,000 crore to ₹2,000 crore incremental revenue opportunity in the branded formulation space for FY27 alone. India may see a sharp rise in adoption of GLP-1 therapy among diabetics, driven by an affordable price point potentially 30 to 50% lower than current levels. Over time, prices could further correct as low as 70 to 75% from current levels.
Experts say that with patent expiry, the generic semaglutide opportunity in India alone could be worth over ₹50 billion, about USD 600 million, in the coming years as multiple players enter the segment.
The Competitors: Who Is Racing and How
This is not a conventional generic drug entry where price is the only variable. Every serious player in the Indian semaglutide race has a differentiated strategy — because in a market where dozens of brands will eventually compete, the ones that win will do so on physician relationships, delivery device innovation, patient support programmes and distribution reach.
Zydus Lifesciences is the most strategically differentiated entrant. A critical differentiator of Zydus’ semaglutide offering is its novel, indigenously developed drug delivery system. Unlike existing treatments that require patients to purchase multiple single-dose pens as they titrate their dosage, Zydus plans to introduce an innovative, adjustable single-pen device that allows patients to seamlessly select and administer varying dose strengths from a single unit, significantly enhancing patient adherence, maximising convenience and drastically reducing the overall cost of therapy. The company launched three brands — Semaglyn, Mashema and Alterme — and has now added Lupin’s distribution muscle through the March 17 licensing agreement.
Dr Sharvil Patel’s articulation of the Zydus thesis is worth quoting in full: “We are not just planning to bring a critical therapy to market, we are aiming to elevate the standard of care. By introducing a first-of-its-kind drug delivery mechanism in India, we plan to simplify the treatment.”
Dr Reddy’s Laboratories is positioning its entry around what it calls a “beyond-the-pill” strategy. The company plans to launch generic semaglutide on Day 1 and is simultaneously building a broader ecosystem that includes Obesity Centres of Excellence, physician education, nutritional products tailored for GLP-1 users and structured patient-support initiatives. Dr Reddy’s Ramana acknowledged the pricing reality directly: “If it is not competitive, and being an out-of-pocket product, then the usage of the product would not be as much.”
While Dr Reddy’s is planning a rollout of semaglutide across 87 countries next year, with Day 1 launches in India and Brazil as patents expire, Cipla is targeting first-wave launches through a mix of in-house and partner filings. Players like Ajanta Pharma and Emcure have already announced partnerships with Biocon and Novo Nordisk to commercialise semaglutide brands in India and international markets.
Sun Pharmaceutical Industries has received regulatory approval from India’s drug regulator to manufacture and market semaglutide and plans to launch the product in multiple dose strengths through user-friendly delivery devices. Natco Pharma has partnered with Eris Lifesciences to bring a generic version to market, combining manufacturing strength with strong presence in the diabetes segment.
The March 17 agreement between Zydus and Lupin is more than a routine licensing deal. It is a recognition by both companies that winning the semaglutide market requires combining Zydus’ product development and device innovation with Lupin’s extensive physician reach and distribution network in the cardiometabolic segment.
Nilesh Gupta, Managing Director of Lupin, described the rationale clearly: “Our partnership with Zydus to market semaglutide injection in India is a significant step in strengthening our commitment to providing advanced treatment options for cardio-metabolic diseases. As GLP-1 therapies continue to redefine treatment standards globally, this collaboration enhances our diabetes portfolio and reinforces our focus on addressing unmet patient needs.”
Lupin brings particular strength in the cardiology and endocrinology prescriber segments — precisely the physicians who will drive semaglutide adoption. Zydus brings the product, the device and the regulatory approvals. Under the agreement, Lupin pays Zydus upfront licensing fees and milestone payments on achieving pre-defined milestones.
Nomura’s Head of Equity Research Saion Mukherjee has identified Dr Reddy’s Laboratories as a prime contender, citing its proficiency in navigating complex regulatory pathways and its established international market presence as critical advantages, including an extensive pipeline of GLP-1 receptor agonists serving both diabetes and obesity treatment segments globally.
Sun Pharmaceutical Industries, with a market capitalisation of approximately ₹4.40 trillion and a P/E ratio of 39.72 as of March 11, 2026, appears positioned to leverage its scale. Zydus Lifesciences, with a lower P/E of 18.62 and market cap of around ₹0.92 trillion, presents a potentially more undervalued profile.
Industry analysts say the wave of semaglutide launches marks an important inflection point for Indian pharma. “The planned entry by companies such as Zydus, Dr Reddy’s and Eris show a deliberate shift into complex peptide manufacturing and high-value injectable therapies,” said Salil Kallianpur, pharma analyst. “GLP-1 drugs are among the fastest-growing global therapy segments. Indian companies positioning themselves here point to a structural upgrade in capability and ambition.”
Kallianpur added: “Scaling peptide synthesis and sterile injectable infrastructure strengthens India’s competitiveness in regulated markets and helps diversify revenues away from commoditised oral generics. If executed well, this could reinforce India’s standing not merely as a volume generics supplier, but as a reliable hub for complex, high-technology therapeutics.”
The opportunity is real. So are the risks.
In India, concerns over the approval of GLP-1 receptor agonists reached the Delhi High Court. Fitness entrepreneur Jitender Chouksey filed a public interest litigation questioning the approval of GLP-1 receptor agonists for obesity without large India-specific clinical trials. The regulatory and legal environment remains a watch point.
A University of Oxford study published in the British Medical Journal in January 2026 found that weight regain after stopping weight-loss drugs occurred faster than after lifestyle-based programmes. Participants regained weight within about 1.7 years of discontinuation, with cardiometabolic gains reversing within roughly 1.4 years. Long-term adherence is therefore a genuine clinical and commercial question — semaglutide works while patients take it, but discontinuation rates in price-sensitive markets may be higher than in the clinical trial populations.
Industry watchers anticipate that market dynamics will shift from premium mono-brand dominance to fragmented branded generics wars, where multiple manufacturers seek share through pricing, pen delivery innovations and distribution networks. Analysts anticipate potential price reductions of 80 to 90% for these treatments — which is excellent for patients but compresses the revenue opportunity significantly for manufacturers competing on price alone.
The companies that survive the price war will be those that have built physician relationships, patient support infrastructure, delivery device advantages and export market access that commodity pricing cannot erode. Zydus, with its pen device advantage and the Lupin distribution partnership announced on March 17, has built the most defensible early position. Dr Reddy’s ecosystem approach gives it a differentiated doctor-facing story. Sun’s scale gives it manufacturing cost advantages that matter when margins compress.
Semaglutide was originally developed and marketed by Novo Nordisk under brands such as Ozempic and Wegovy and has become one of the fastest-growing drug categories in the world due to its strong results in blood sugar control and weight reduction. India spent years watching that revolution happen elsewhere, at prices that put it out of reach for the vast majority of its diabetic and obese population.
This article is for informational purposes only.